PharmaPath’s commitment to RnD is a key growth driver, firmly connected to our mission and out-licensing business strategy.
Our out-licensing portfolio primarily focuses on our in-house developed dossiers of oral solid dosage forms (immediate and extended release tablets and capsules), allowing Day 1 generic entry for our partners upon patent expiry.
10 Tips For bla bla bla
bla bla bla bla
Our fully integrated development activities range from pre-formulation to formulation and analytical development, scale-up, process validation, stability testing and clinical phase design and execution. We adopt a QbD approach to our product development allowing the implementation of processes that achieve a consistent level of quality and efficiency further supporting our reliable supply.
We are constantly seeking reliable partners in the R&D field to add new products to our portfolio through technology transfer or co-development projects. If you are interested in developing a partnerships with us, please contact us at BD@pharmapath.eu